Search

Search Constraints

You searched for: Author/Creator Zhu, Lingjun

Search Results

3. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. (November 2022)